Thiostrepton may be combined with chemotherapy targeting breast and ovarian cancers through its ability to inhibit the expression of the cancer stemness regulator FOXM1, which leads to attenuation of stemness [49] and chemosensitivity [50], respectively. The gene discussed is FOXM1; the disease is cancer.